CSGALNACT2

Across TCGA pan-cancer cohorts, CSGALNACT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CSGALNACT2 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CSGALNACT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CSGALNACT2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where CSGALNACT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.467	0.977	<.001	67	view →
HNSC	OS	Quartile	All	0.912	0.760	.005	13	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	7	view →
GBM	OS	Median	All	0.735	0.891	.022	2	view →
LUAD	OS	Quartile	III,IV	0.648	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CSGALNACT2–PDAC (OS)

Open the PDAC breakdown →